
Erratum

Erratum to: A Novel Transdermal Delivery System for the Anti-Inflammatory Lumiracoxib: Influence of Oleic Acid on *In Vitro* Percutaneous Absorption and *In Vivo* Potential Cutaneous Irritation

Tailane Sant'Anna Moreira,¹ Valéria Pereira de Sousa,² and Maria Bernadete Riemma Pierre^{1,3}

Published online 27 April 2010

In the section “Material and Methods—Chemicals” it was stated that the drug lumiracoxib was provided by Novartis Pharmaceuticals (São Paulo, SP, Brazil). However, for use in experiments described specifically in this article, this drug was extracted from tablets of Prexige® 400 mg (Novartis) according to methodology previously described in detail by our research group (1).

1. Moreira TS, Cid YP, Pierre MBR, Kummerle AE, Fraga CAM, Sousa VP. Extração e purificação de fármacos antiinflamatórios não esteroidais ciclooxygenase-2 seletivos. *Química Nova*. 2009;32(5):1324–8.

The online version of the original article can be found under doi:10.1208/s12249-010-9420-1

¹ School of Pharmacy, Pharmaceutical Technology Laboratory, Department of Medicine, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho, 373, 21.941.590, Rio de Janeiro, Brazil.

² School of Pharmacy, Quality Control Laboratory, Department of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.

³ To whom correspondence should be addressed. (e-mail: bernadete@pharma.ufrj.br)